2024/02/02 更新

写真a

イセキ　ユウコ
井関　ゆう子
Iseki Yuko
所属
付属病院 リウマチ・膠原病内科 講師
職名
講師
外部リンク

研究キーワード

  • 膠原病

  • 強皮症

  • 間質性肺疾患

  • 線維化

研究分野

  • ライフサイエンス / 膠原病、アレルギー内科学  / 膠原病

経歴

  • 日本医科大学大学院医学研究科   アレルギー膠原病内科学分野

    2022年5月 - 現在

    　 詳細を見る

    国名：日本国

    researchmap

  • 日本医科大学   アレルギー膠原病内科学分野   助教

    2019年3月 - 2022年4月

    　 詳細を見る

  • 米国国立アレルギー感染症研究所   Post doctoral fellow

    2013年10月 - 2019年1月

    　 詳細を見る

  • 東京女子医科大学   膠原病リウマチ痛風センター

    2010年4月 - 2013年9月

    　 詳細を見る

  • 都立大塚病院   リウマチ膠原病科

    2009年4月 - 2010年3月

    　 詳細を見る

  • 東京女子医科大学   膠原病リウマチ痛風センター

    2008年4月 - 2009年3月

    　 詳細を見る

  • 東京女子医科大学   糖尿病センター内科

    2007年4月 - 2008年3月

    　 詳細を見る

  • 東京女子医科大学   研修医

    2005年4月 - 2007年3月

    　 詳細を見る

▼全件表示

所属学協会

委員歴

  • 日本リウマチ学会   評議員  

    2017年 - 現在   

    　 詳細を見る

    団体区分：学協会

    researchmap

論文

  • Updates on genetics in systemic sclerosis. 査読 国際誌

    Yuko Ota, Masataka Kuwana

    Inflammation and regeneration   41 ( 1 )   17 - 17   2021年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Systemic sclerosis (SSc) is a complex disease, in which an interaction of genetic and environmental factors plays an important role in its development and pathogenesis. A number of genetic studies, including candidate gene analysis and genome-wide association study, have found that the associated genetic variants are mainly localized in noncoding regions in the expression quantitative trait locus and influence corresponding gene expression. The gene variants identified as a risk for SSc susceptibility include those associated with innate immunity, adaptive immune response, and cell death, while there are only few SSc-associated genes involved in the fibrotic process or vascular homeostasis. Human leukocyte antigen class II genes are associated with SSc-related autoantibodies rather than SSc itself. Since the pathways between the associated genotype and phenotype are still poorly understood, further investigations using multi-omics technologies are necessary to characterize the complex molecular architecture of SSc, identify biomarkers useful to predict future outcomes and treatment responses, and discover effective drug targets.

    DOI： 10.1186/s41232-021-00167-6

    PubMed

    researchmap

  • Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis. 査読 国際誌

    Yuko Ota, Masataka Kuwana

    European journal of rheumatology   1 - 8   2019年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive fibrosis, microvasculopathy, and autoimmunity. Endothelial cell (EC) injury and subsequent endothelial cell dysfunction is believed to be an initial event that eventually leads to a vicious pathogenic cycle. This process is further enhanced by defective angiogenesis and vasculogenesis, as the vascular repair machinery does not work properly. Endothelial progenitor cells (EPCs) are functionally and quantitatively insufficient to recover the endothelium in SSc patients. The dysfunctional ECs and EPCs not only trigger the formation of typical vascular lesions, such as progressive intimal fibrosis in small arteries and the loss of capillaries, but also promote a series of inflammatory and profibrotic processes, such as endothelial-mesenchymal transition and recruitment and accumulation of monocytic EPCs with profibrotic properties. These processes together contribute to the accumulation of extracellular matrix in the affected tissue. This review features current insights into the roles of ECs and EPCs in the pathogenesis of SSc.

    DOI： 10.5152/eurjrheum.2019.19158

    PubMed

    researchmap

  • Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis 査読

    Tomoaki Higuchi, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuko Ota, Yasuhiro Katsumata, Hisae Ichida, Masanori Hanaoka, Hidenaga Kawasumi, Mari Tochihara, Hisashi Yamanaka

    CLINICAL IMMUNOLOGY   161 ( 2 )   333 - 338   2015年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Systemic sclerosis (SSc) is a multi-organ fibrotic disease that affects the skin and various internal organs. Therapeutic strategies for tissue fibrosis have not been established; however, aberrantly activated fibroblasts in affected lesions are key targets for modulating fibrosis. Recently, increased intracellular cyclic GMP (cGMP) levels were demonstrated to improve fibrosis levels in various diseases. The purpose of this study was to assess the antifibrotic properties of cGMP in cultured fibroblasts from patients with SSc. The phosphodiesterase (PDE) 5 inhibitor sildenafil increased the intracellular cGMP levels in skin fibroblasts in a dose-dependent manner. Sildenafil treatment also significantly decreased the expression of several pro-fibrotic factors that were upregulated by TGF-beta 1 treatment in SSc skin fibroblasts. These inhibitory effects occurred via non-canonical TGF-beta signaling. Our findings revealed that sildenafil might be a novel strategy to treat tissue fibrosis and vasculopathy in SSc. (C) 2015 Elsevier Inc. All rights reserved.

    DOI： 10.1016/j.clim.2015.09.010

    Web of Science

    researchmap

  • Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease 査読

    Takahisa Gono, Hirotaka Kaneko, Yasushi Kawaguchi, Masanori Hanaoka, Sayuri Kataoka, Masataka Kuwana, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Yuko Ota, Hidenaga Kawasumi, Hisashi Yamanaka

    RHEUMATOLOGY   53 ( 12 )   2196 - 2203   2014年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：OXFORD UNIV PRESS  

    Objective. PM and DM are often complicated by interstitial lung disease (ILD). In this study we aimed to evaluate various serum cytokines in patients with PM/DM with ILD so as to clarify the differences in pathophysiology between anti-melanoma differentiation-associated gene 5 antibody-associated ILD (anti-MDA5-ILD) and anti-aminoacyl tRNA synthetase antibody-associated ILD (anti-ARS-ILD).
    Methods. We evaluated the serum cytokine profiles of 38 patients with PM/DM and compared the cytokine profiles of the non-ILD and ILD subsets as well as the anti-MDA5-ILD and anti-ARS-ILD subsets.
    Results. The myositis intention-to-treat activity index score, which indicates whole disease activity, significantly correlated with serum IL-6, IL-8, TNF-alpha and IP-10. These cytokine levels were significantly higher in the ILD subset than the non-ILD subset and were lower in the ILD subset following treatment. By multivariate analysis, TNF-alpha was the most significant cytokine [P = 0.0006, odds ratio (OR) 1.4, CI 1.1, 2.2] associated with PM/DM with ILD. IL-8 levels were significantly higher in anti-MDA5-ILD than in anti-ARS-ILD, although IL-6, TNF-alpha and IP-10 levels were high in both subsets. IL-8 was the most significant cytokine (P = 0.0006, OR 1.5, CI 1.1, 3.0) associated with anti-MDA5-ILD by multivariate analysis. Moreover, the ratio of IL-4 to IFN-gamma was lower in anti-MDA5-ILD than in anti-ARS-ILD.
    Conclusion. IL-6, IL-8, TNF-alpha and IP-10 are associated with global disease activity in PM/DM. These cytokine levels were high, especially in the ILD subset. Serum IL-8 levels and the balance between IL-4 and IFN-gamma may contribute to the differences in pathophysiology between anti-ARS-ILD and anti-MDA5-ILD.

    DOI： 10.1093/rheumatology/keu258

    Web of Science

    researchmap

  • Clinical Manifestations of Adult-Onset Still's Disease Presenting With Erosive Arthritis: Association With Low Levels of Ferritin and Interleukin-18 査読

    Hisae Ichida, Yasushi Kawaguchi, Tomoko Sugiura, Kae Takagi, Yasuhiro Katsumata, Takahisa Gono, Yuko Ota, Sayuri Kataoka, Hidenaga Kawasumi, Hisashi Yamanaka

    ARTHRITIS CARE & RESEARCH   66 ( 4 )   642 - 646   2014年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY-BLACKWELL  

    ObjectiveAdult-onset Still's disease (AOSD) is a clinical entity with a heterogeneous etiology. We have encountered patients with AOSD who had severe polyarthritis and who fulfilled the classification criteria for rheumatoid arthritis (RA); however, most patients with AOSD typically exhibit mild arthritis. In this study, we proposed 2 clinical subsets of AOSD and investigated the clinically significant characteristics of the 2 subtypes.
    MethodsWe retrospectively analyzed 71 consecutive patients with AOSD. We reviewed the medical records of all patients who were followed up for more than 2 years. We classified all of the patients with AOSD into the following 2 subsets: an RA subtype for patients who met the criteria for RA according to the American College of Rheumatology and a non-RA subtype for patients who did not meet the criteria for RA.
    ResultsOur results indicated that the non-RA subtype was accompanied by severe inflammatory complications, including pleuritis and hemophagocytic syndrome. In addition, the serum ferritin and serum interleukin-18 (IL-18) levels were significantly higher in patients with the non-RA subtype than in those with the RA subtype. Interestingly, only 1 patient with the RA subtype had anti-cyclic citrullinated peptide antibodies and 1 patient with the non-RA subtype had rheumatoid factor. These findings distinguish these patients from patients with true RA.
    ConclusionThere were 2 subsets of patients with AOSD in the examined population. Patients with high levels of IL-18 or ferritin presented with severe systemic inflammatory disorders (non-RA subtype) and patients with low levels of IL-18 or ferritin developed severe arthritis (RA subtype).

    DOI： 10.1002/acr.22194

    Web of Science

    researchmap

  • Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis 査読

    Yuko Ota, Yasushi Kawaguchi, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Tomoaki Higuchi, Hisashi Yamanaka

    Clinical Immunology   147 ( 2 )   71 - 78   2013年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Systemic sclerosis (SSc) is a connective tissue disease characterized by thickening of the skin and tissue fibrosis of the internal organs. Ghrelin is primarily described as a gut hormone, and many studies currently indicate that ghrelin has protective effects in different organs, including the heart, pancreas, lung and liver, resulting from its anti-fibrotic properties. We found decreased levels of ghrelin in the plasma from patients with SSc compared with those from healthy controls. In skin fibroblast cultures, recombinant ghrelin diminished the production of collagen type I. In addition, the mRNA levels of COL1A2 and TGFB genes were significantly decreased by the stimulation of ghrelin. We showed that ghrelin may exert anti-fibrotic effects in the skin fibroblasts from patients with SSc. Because the plasma levels of ghrelin are low in SSc, the administration of ghrelin could be a new strategy for the treatment of SSc. © 2013 Elsevier Inc.

    DOI： 10.1016/j.clim.2013.03.001

    Scopus

    PubMed

    researchmap

  • PLD4 as a Novel Susceptibility Gene for Systemic Sclerosis in a Japanese Population 査読

    Chikashi Terao, Koichiro Ohmura, Yasushi Kawaguchi, Tetsuya Nishimoto, Aya Kawasaki, Kazuhiko Takehara, Hiroshi Furukawa, Yuta Kochi, Yuko Ota, Katsunori Ikari, Shinichi Sato, Shigeto Tohma, Ryo Yamada, Kazuhiko Yamamoto, Michiaki Kubo, Hisashi Yamanaka, Masataka Kuwana, Naoyuki Tsuchiya, Fumihiko Matsuda, Tsuneyo Mimori

    ARTHRITIS AND RHEUMATISM   65 ( 2 )   472 - 480   2013年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY-BLACKWELL  

    Objective. Systemic sclerosis (SSc) is an autoimmune disease for which multiple susceptibility genes have been reported. Genome-wide association studies have shown that large numbers of susceptibility genes are shared among autoimmune diseases. Recently, our group identified 9 novel susceptibility genes associated with rheumatoid arthritis (RA) in a Japanese population. The aim of this study was to elucidate whether the 18 genes that displayed associations or suggestive associations for RA in our previous study are associated with SSc in Japanese.
    Methods. We performed an association study that included 415 patients with SSc and 16,891 control subjects, followed by a replication study that included 315 patients and 21,054 control subjects. The 18 markers reported to display association with RA were analyzed for their associations with SSc in the first study, and 5 markers were further analyzed in the replication study. The inverse variance method was used to evaluate the associations of these markers with SSc in a combined study.
    Results. In the phospholipase D4 gene (PLD4), rs2841277 displayed a significant association with SSc in Japanese patients (P = 0.00017). We observed that rs2841280 in exon 2 of PLD4 was in strong linkage disequilibrium with rs2841277 and introduced an amino acid alteration. We also observed associations between SSc and rs6932056 in TNFAIP3 and rs2280381 in IRF8 (P = 0.0000095 and P = 0.0030, respectively), both of which displayed associations with SSc in a European population.
    Conclusion. We determined that PLD4 is a novel susceptibility gene for SSc in Japanese, thus confirming the involvement of PLD4 in autoimmunity. Associations between SSc and TNFAIP3 or IRF8 were also detected in our Japanese population. SSc and RA appear to share relatively large proportions of their genetic backgrounds.

    DOI： 10.1002/art.37777

    Web of Science

    researchmap

  • Brief Report Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population 査読

    Takahisa Gono, Yasushi Kawaguchi, Masataka Kuwana, Tomoko Sugiura, Takefumi Furuya, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Masanori Hanaoka, Yuko Ota, Hisashi Yamanaka

    ARTHRITIS AND RHEUMATISM   64 ( 11 )   3736 - 3740   2012年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY-BLACKWELL  

    Objective. The complication of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) is associated with anti-aminoacyl-transfer RNA synthetase (anti-aaRS) antibody or anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibody positivity. Anti-MDA-5 antibody is associated with clinically amyopathic DM and fatal outcome due to rapidly progressive ILD in Asian populations. The association between genetic factors and anti-MDA-5 antibody-positive DM is unclear. This study was undertaken to investigate the HLA-DRB1 genotype in patients with anti-MDA-5 antibody-positive DM.
    Methods. We examined genetic differences among 17 patients with anti-MDA-5 antibody-positive DM, 33 patients with anti-aaRS antibody-positive PM/DM, 33 patients with PM/DM without anti-aaRS antibody or ILD, and 265 healthy controls.
    Results. The frequencies of HLA-DRB1*0101 and DRB1*0405 were 29% and 71%, respectively, in patients with anti-MDA-5 antibody-positive DM, which were higher than the frequencies in healthy controls (10% and 25%, respectively). Among the 17 patients with anti-MDA-5 antibody-positive DM, 16 (94%) harbored either the DRB1*0101 or DRB1*0405 allele. The com-bined frequency of the DRB1*0101 allele and the DRB1*0405 allele was significantly higher in patients with anti-MDA-5 antibody-positive DM than in patients with PM/DM without anti-aaRS antibody or ILD, with an odds ratio (OR) of 42.7 (95% confidence interval [95% CI] 4.9-370.2) (P = 1.1 x 10(-5)), or in patients with anti-aaRS antibody-positive PM/DM (OR 13.3 [95% CI 1.6-112.6], P = 4.5 x 10(-3)).
    Conclusion. Our findings indicate that HLA-DRB1*0101/*0405 is associated with susceptibility to anti-MDA-5 antibody-positive DM in the Japanese population.

    DOI： 10.1002/art.34657

    Web of Science

    researchmap

  • Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease 査読

    Toshio Odani, Shinsuke Yasuda, Yuko Ota, Yuichiro Fujieda, Yujiro Kon, Tetsuya Horita, Yasushi Kawaguchi, Tatsuya Atsumi, Hisashi Yamanaka, Takao Koike

    RHEUMATOLOGY   51 ( 10 )   1765 - 1774   2012年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：OXFORD UNIV PRESS  

    Objective. Interstitial lung disease (ILD) is a serious complication of SSc. We aimed to identify markers associated with SSc-related ILD.
    Methods. RNA was prepared from the peripheral blood mononuclear cells of 14 SSc patients, divided into four different RNA pools according to the presence or absence of ILD and to the treatment, and subjected to microarray analysis. Real-time quantitative PCR was used to confirm the microarray results in 43 SSc patients, 42 autoimmune controls and 10 healthy controls. Genomic DNA samples were collected from 149 patients with SSc (70 in Hokkaido and 79 in Tokyo) who underwent a high-resolution CT for the evaluation of ILD and from 230 healthy controls. Genotyping was performed using sequence-specific primers.
    Results. The microarray analysis revealed HLA-DRB5 to be the only gene commonly up-regulated in patients with ILD compared with those without ILD in both comparison groups. High expression levels of HLA-DRB5 in SSc patients with ILD were confirmed by real-time quantitative PCR. The prevalence of HLA-DRB5 gene carriers increased in the SSc patients with ILD relative to those without ILD or to healthy controls in both cohorts. Among the four detected alleles, the HLA-DRB5*01:05 allele was significantly more frequent in SSc patients with ILD than in SSc patients without ILD or in healthy controls. These associations were confirmed in the second cohort.
    Conclusion. HLA-DRB5 was highly expressed in PBMCs from patients with SSc-related ILD. The HLA-DRB5*01:05 allele is a risk factor for ILD in patients with SSc.

    DOI： 10.1093/rheumatology/kes149

    Web of Science

    researchmap

  • Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis 査読

    Takahisa Gono, Shinji Sato, Yasushi Kawaguchi, Masataka Kuwana, Masanori Hanaoka, Yasuhiro Katsumata, Kae Takagi, Sayumi Baba, Yuko Okamoto, Yuko Ota, Hisashi Yamanaka

    RHEUMATOLOGY   51 ( 9 )   1563 - 1570   2012年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：OXFORD UNIV PRESS  

    Objective. The aim of this study was to investigate the precise clinical characteristics and to analyse the association between the anti-MDA5 antibody (anti-MDA5ab) titre and disease status in patients with anti-MDA5ab-positive DM.
    Methods. Twenty-seven patients who presented with DM and were positive for the anti-MDA5ab were enrolled. The association between the clinical manifestations and the clinical parameters, including the anti-MDA5ab, was analysed.
    Results. The complication of rapidly progressive interstitial lung disease (RP-ILD) occurred in 20 (74%) patients. The frequencies of fatal outcome, relapse and malignancy were 33, 4 and 4%, respectively. Remarkably, a fatal outcome occurred within the first 6 months. Compared with six non-RP-ILD patients, elderly age at onset, severely involved pulmonary function and high levels of serum ferritin were present in 20 RP-ILD patients with anti-MDA5ab. Alveolar-arterial oxygen difference (AaDO(2)) epsilon 32 mmHg and ferritin epsilon 828 ng/ml at admission were poor prognostic factors in RP-ILD patients with anti-MDA5ab-positive DM. The median value of the anti-MDA5ab titre on admission was higher in patients who later died than in those who survived. The efficacy of treatment was indicated by the anti-MDA5ab, ferritin and IL-18 concentrations. The decline index of the anti-MDA5ab titre after treatment was lower in the subset of patients who died than in the subset of patients who lived. Sustained high levels of anti-MDA5ab, ferritin and IL-18 were present in the patients who died.
    Conclusion. Anti-MDA5ab titre and ferritin and IL-18 concentrations are useful for the evaluation of the response to treatment and the status of ILD in patients with anti-MAD5ab-positive DM.

    DOI： 10.1093/rheumatology/kes102

    Web of Science

    researchmap

  • Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up 査読

    Akiko Tochimoto, Yasushi Kawaguchi, Masako Hara, Mutsuto Tateishi, Chikako Fukasawa, Kae Takagi, Emi Nishimagi, Yuko Ota, Yasuhiro Katsumata, Takahisa Gono, Eiichi Tanaka, Hisashi Yamanaka

    MODERN RHEUMATOLOGY   21 ( 3 )   296 - 301   2011年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：SPRINGER  

    Interstitial lung disease (ILD) is a noteworthy condition in the treatment of systemic sclerosis (SSc) because of its associated mortality and morbidity; however, the efficacy of various treatments for ILD has been controversial in previous reports. In this study, we examined the efficacy and safety of intravenous cyclophosphamide (IVCY) pulse therapy with prednisolone (PSL) for the treatment of ILD with SSc. A total of 121 patients with SSc were screened and evaluated for ILD, using high-resolution computed tomography of the chest, pulmonary function testing, and bronchoalveolar lavage. Thirteen patients with active ILD were enrolled in this study. The treatment protocol for ILD was 0.4 g/m(2) of body surface area of IVCY monthly plus 0.8 mg/kg of body weight of PSL daily. Two to six doses of IVCY were administered, depending on the remission of ILD. Initial PSL doses were maintained for a month and then gradually tapered to 10 mg daily. An activity index of ILD showed improvements in all patients in the 12 months after the initial intervention; however, four patients experienced recurrence of ILD after 24 months, and one additional patient had recurrence of ILD after 36 months. Seven patients reached the 48-month point with no recurrence of ILD. This long observational study for 48 months showed the efficacy of IVCY with PSL for active alveolitis in the first year. However, because five patients had recurrence of ILD more than 1 year after the treatment, it would be necessary to consider maintenance therapy for ILD beyond 1 year.

    DOI： 10.1007/s10165-010-0403-6

    Web of Science

    researchmap

  • Activation of the Activin A-ALK-Smad pathway in systemic sclerosis 査読

    Kae Takagi, Yasushi Kawaguchi, Manabu Kawamoto, Yuko Ota, Akiko Tochimoto, Takahisa Gono, Yasuhiro Katsumata, Masatoshi Takagi, Masako Hara, Hisashi Yamanaka

    JOURNAL OF AUTOIMMUNITY   36 ( 3-4 )   181 - 188   2011年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Systemic sclerosis (SSc) is a chronic disease of unknown etiology that is characterized by multiple tissue fibrosis. Transforming Growth Factor-beta (TGF-beta) is thought to be the most important mediator that induces fibrosis. However, the molecular mechanisms by which fibrosis is induced have not been fully elucidated. In this study, the role of activin, a member of the TGF-beta superfamily, was investigated in the pathogenesis of fibrosis in SSc. Serum activin A levels in patients with SSc were measured by ELISA, and the expression of the activin receptor type IB (ACVRIB/ALK4) and the activity of the signaling pathway via ACVRIB/ALK4 were investigated using western blotting. To evaluate a potential therapeutic strategy for SSc, we also attenuated the ACVRIB/ALK4 pathway using an inhibitor. Serum activin A levels were significantly higher in SSc patients than in normal controls. Activin A and ACVRIB/ALK4 expression were also higher in cultured SSc fibroblasts. Activin A stimulation induced phosphorylation of Smad2/3 and CTGF expression in SSc fibroblasts. Procollagen production and Col1 alpha mRNA also increased upon stimulation by activin A. The basal level of Smad2/3 phosphorylation was higher in cultured SSc fibroblasts than in control cells, and treatment with the ALK4/5 inhibitor SB431542 prevented phosphorylation of Smad2/3 and CTGF expression. Furthermore, production of collagen was also induced by activin A. Activin A-ACVRIB/ALK4-Smad-dependent collagen production was augmented in SSc fibroblasts, suggesting the involvement of this signaling mechanism in SSc. Inhibition of the activin A-ACVRIB/ALK4-Smad pathway would be a new approach for the treatment of SSc. (C) 2010 Elsevier Ltd. All rights reserved.

    DOI： 10.1016/j.jaut.2010.09.004

    Web of Science

    researchmap

  • Clinical manifestations of neurological involvement in primary Sjögren’s syndrome. 査読

    Gono T, Kawaguchi Y, Katsumata Y, Takagi K, Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H

    Clin Rheumatol   30 ( 4 )   485 - 490   2011年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s10067-010-1458-7

    Web of Science

    researchmap

  • Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis 査読

    Takahisa Gono, Yasushi Kawaguchi, Eri Ozeki, Yuko Ota, Takashi Satoh, Masataka Kuwana, Masako Hara, Hisashi Yamanaka

    MODERN RHEUMATOLOGY   21 ( 2 )   223 - 227   2011年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：SPRINGER  

    Dermatomyositis (DM) is occasionally complicated by interstitial lung disease. Acute/subacute interstitial pneumonia (A/SIP) with DM is intractable and life threatening. Clinically amyopathic dermatomyositis (C-ADM) is also reported to be complicated with A/SIP, especially in those patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody. In the present cases, we indicate that serum ferritin level correlated with activity of A/SIP with DM. Two patients, a 65-year-old woman and a 30-year-old woman, were diagnosed with anti-MDA5 antibody-associated A/SIP with DM. Serum ferritin was high, 1600 and 770 mg/dl, respectively, on admission. Immunosuppressive therapy ameliorated A/SIP in both cases. Similarly, serum ferritin was also decreasing. However, A/SIP was recurrent and progressive, and serum ferritin was also increasing again in one case. In conclusion, serum ferritin correlates with disease activity of anti-MDA5 antibody-associated A/SIP with DM. Intensity of treatment may be decided according to serum ferritin level.

    DOI： 10.1007/s10165-010-0371-x

    Web of Science

    researchmap

  • Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease 査読

    Takahisa Gono, Yasushi Kawaguchi, Tomoko Sugiura, Hisae Ichida, Kae Takagi, Yasuhiro Katsumata, Masanori Hanaoka, Yuko Okamoto, Yuko Ota, Hisashi Yamanaka

    RHEUMATOLOGY   49 ( 10 )   1878 - 1881   2010年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：OXFORD UNIV PRESS  

    Objective. To determine whether IL-18 is involved in the inflammation of DM and PM.
    Methods. Thirty-three patients with DM were enrolled in this study, including 25 with interstitial lung disease (ILD). In addition, 16 patients with PM were enrolled, including 6 with ILD. All patients were admitted to our hospital as a result of their condition requiring treatment, and clinical laboratory data including serum IL-18 were recorded on admission.
    Results. Serum IL-18 was significantly (P < 0.0001) higher in both DM and PM patients than in healthy controls (n = 30). Serum ferritin and IL-18 were significantly (P = 0.003 and 0.0044, respectively) higher in DM than in PM patients. Additionally, ferritin and IL-18 were significantly (P = 0.023 and 0.034, respectively) higher in DM patients with ILD than in DM patients without ILD. Significant positive correlations were found between creatine kinase (CK) and ferritin (r(s) = 0.39, P = 0.024); CK and IL-18 (r(s) = 0.48, P = 0.005); and IL-18 and ferritin (r(s) = 0.54, P = 0.0012) in the DM group as a whole. These findings were different for the DM plus ILD subgroup: significant positive correlations were found between CK and ferritin (r(s) = 0.40, P = 0.047); CK and IL-18 (r(s) = 0.63, P = 0.0008); and IL-18 and ferritin (r(s) = 0.41, P = 0.042).
    Conclusion. Serum IL-18 was strikingly elevated in patients with DM and was associated particularly with disease activity and ILD complication in DM.

    DOI： 10.1093/rheumatology/keq196

    Web of Science

    researchmap

  • Single nucleotide polymorphisms of CD244 gene predispose to renal and neuropsychiatric manifestations with systemic lupus erythematosus 査読

    Yuko Ota, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Manabu Kawamoto, Yasuhiro Katsumata, Takahisa Gono, Ikuko Masuda, Katsunori Ikari, Shigeki Momohara, Hisashi Yamanaka

    MODERN RHEUMATOLOGY   20 ( 5 )   427 - 431   2010年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：SPRINGER  

    The objective of this study was to explore the association of single nucleotide polymorphisms (SNPs) of the CD244 gene with several clinical features of systemic lupus erythematosus (SLE). Two hundred and forty-three patients with SLE and 369 healthy controls were enrolled. Two SNPs (rs6682654 and rs3766379) in the CD244 gene were determined by allelic discrimination using a specific TaqMan probe. Only SNP rs3766379 was significantly associated with susceptibility to SLE [P = 0.009; odds ratio (OR) 1.28; 95% confidence interval (CI) 1.04-1.57]. The association was preferentially observed in subsets of SLE patients with nephritis and neuropsychiatric lupus. The frequency of the rs6682654 C allele was strongly associated with nephritis and neuropsychiatric lupus (P = 0.00065; OR 1.99; 95% CI 1.34-2.95, and P = 1.6 x 10(-7); OR 3.47; 95% CI 2.12-5.70, respectively), as was the frequency of the rs3766379 T allele (P = 0.0014; OR 1.86; 95% CI 1.27-2.71, and P = 2.6 x 10(-7); OR 3.15; 95% CI 2.00-4.96, respectively). In this study, an SNP of the CD244 gene was associated with susceptibility to SLE. There was a strikingly strong association in SLE patients with nephritis and neuropsychiatric lupus, suggesting that this genetic marker could predict involvement of those severe complications.

    DOI： 10.1007/s10165-010-0302-x

    Web of Science

    researchmap

  • Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis 査読

    Takahisa Gono, Yasushi Kawaguchi, Takashi Satoh, Masataka Kuwana, Yasuhiro Katsumata, Kae Takagi, Ikuko Masuda, Akiko Tochimoto, Sayumi Baba, Yuko Okamoto, Yuko Ota, Hisashi Yamanaka

    RHEUMATOLOGY   49 ( 9 )   1713 - 1719   2010年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：OXFORD UNIV PRESS  

    Methods. Fourteen patients who presented with anti-MDA5 antibody and 10 patients with anti-aminoacyl-tRNA synthetase (ARS) antibody were enrolled. All patients were diagnosed as having DM with ILD. Clinical manifestations in the patients with anti-MDA5 antibody were compared with those in the patients with anti-ARS antibody.
    Results. The frequencies of acute/subacute interstitial pneumonia (A/SIP) and fatal outcome were significantly higher in the subset with anti-MDA5 antibody. The creatine kinase (CK) value was significantly lower and the gamma-glutamyl transpeptidase and ferritin values were significantly higher in the subset with anti-MDA5 antibody. Significant correlations were found between PaO(2)/F(i)O(2) and ferritin (r(s) = -0.59, P = 0.035), alveolar-arterial oxygen difference (A-aDO(2)) and KL-6 (r(s) = 0.73, P = 0.016) and A-aDO(2) and ferritin (r(s) = 0.66, P = 0.013) in the subset with anti-MDA5 antibody. The most significant prognostic factor was ferritin. The cumulative survival rate was significantly lower (P < 0.0001) in the subset with ferritin epsilon 1600 ng/ml than that in the subset with ferritin < 1600 ng/ml in anti-MDA5 antibody-associated ILD.
    Conclusion. Both serum ferritin and anti-MDA5 antibody are powerful indicators for the early diagnosis of A/SIP with DM. Ferritin also predicts disease severity and prognosis for patients with anti-MDA5 antibody. Intensive treatment should be administered to cases that have anti-MDA5 antibody-associated ILD with DM showing hyperferritinaemia, especially if the ferritin level is epsilon 1600 ng/ml.

    DOI： 10.1093/rheumatology/keq149

    Web of Science

    researchmap

  • Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis 査読

    Takahisa Gono, Yasushi Kawaguchi, Masako Hara, Ikuko Masuda, Yasuhiro Katsumata, Mikiko Shinozaki, Yuko Ota, Eri Ozeki, Hisashi Yamanaka

    RHEUMATOLOGY   49 ( 7 )   1354 - 1360   2010年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：OXFORD UNIV PRESS  

    Objectives. Acute/subacute interstitial pneumonia (A/SIP) is an intractable and fatal complication of DM. Since a useful indicator predicting the complication of A/SIP has not been found, the aim of this study was to determine whether serum ferritin is a potential predictive indicator of the occurrence of A/SIP in 64 patients with DM.
    Methods. Of the total patients enrolled, 19 had A/SIP, 24 had chronic interstitial pneumonia and 21 were without interstitial lung disease (ILD). Clinical manifestations and laboratory data were obtained from medical records on admission.
    Results. Serum ferritin levels were extremely high in patients with DM with A/SIP. It was significantly higher in DM with A/SIP than that in DM without A/SIP (median 790 vs 186 ng/ml; P<0.0001). The cumulative survival rate for 6 months was 62.7% in patients with DM with A/SIP. Moreover, the cumulative survival rate was significantly (P = 0.016) lower in the group with ferritin levels >= 1500 ng/ml than the rate in the group with ferritin levels < 1500 ng/ml.
    Conclusions. Serum ferritin can be useful as a predictor of the occurrence of A/SIP and correlates with the prognosis of A/SIP in DM. The intensive treatment using combination therapy with various immunosuppressant agents should be chosen for patients with ILD with DM showing hyperferritinaemia, especially levels > 1500 ng/ml.

    DOI： 10.1093/rheumatology/keq073

    Web of Science

    researchmap

  • Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population 査読

    Y. Kawaguchi, Y. Ota, M. Kawamoto, I. Ito, N. Tsuchiya, T. Sugiura, Y. Katsumata, M. Soejima, S. Sato, M. Hasegawa, M. Fujimoto, K. Takehara, M. Kuwana, H. Yamanaka, M. Hara

    ANNALS OF THE RHEUMATIC DISEASES   68 ( 12 )   1921 - 1924   2009年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：B M J PUBLISHING GROUP  

    Objectives: To validate the association of a single nucleotide polymorphism (SNP) of the connective tissue growth factor gene (CTGF) with susceptibility to systemic sclerosis (SSc) in the Japanese population.
    Methods: 395 Japanese patients with SSc, 115 patients with rheumatoid arthritis and 269 healthy Japanese volunteers were enrolled in the study. An SNP (rs6918698) at -945 bp from the start codon in the promoter region of the CTGF gene was determined by allelic discrimination with the use of a specific TaqMan probe.
    Results: The G allele showed a significantly higher frequency in patients with SSc than in controls (p<0.001; odds ratio 1.5; 95% confidence interval 1.2 to 1.9). In particular, the clinical subsets of SSc showed a more significant association between the G allele and diffuse cutaneous SSc (p<0.001) and the presence of interstitial lung disease (p<0.001), the presence of anti-topoisomerase I antibody (p<0.001) and anti-U1RNP antibody (p = 0.010). Association analyses using the genotype of the SNP yielded results similar to those of analyses using the allele.
    Conclusions: This study confirms the association between an SNP in the CTGF gene and susceptibility to SSc, especially in the presence of diffuse cutaneous SSc, interstitial lung disease and anti-topoisomerase I antibody. The results strongly suggest that this SNP may be a powerful indicator of severe skin and lung involvement in patients with SSc.

    DOI： 10.1136/ard.2008.100586

    Web of Science

    researchmap

  • Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis

    Kawaguchi, Yasushi, Nakamura, Yumi, Matsumoto, Isao, Ota, Yuko, Nishimagi, Emi, Kamatani, Naoyuki, Satoh, Takashi, Kuwana, Masataka, Sumida, Takayuki, Hara, Masako

    ARTHRITIS AND RHEUMATISM   58 ( 9::Suppl. S )   0 - 0   2008年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY-LISS  

    researchmap

▼全件表示

MISC

  • 中下位頚椎病変による頚部痛が初発症状となった関節リウマチの一例

    齊藤有希子, 渡邊晋二, 吉田晃, 大田ゆう子, 白井悠一郎, 五野貴久, 岳野光洋, 桑名正隆

    関東リウマチ   54   2022年

    　詳細を見る

  • トシリズマブ中断後に多房性膿胸を発症した若年性特発性関節炎の1例

    鈴木 幹人, 名和田 隆司, 櫻庭 未多, 大田 ゆう子, 白井 悠一郎, 五野 貴久, 岳野 光洋, 渥美 健一郎, 林 宏紀, 桑名 正隆

    日本内科学会関東地方会   656回   43 - 43   2019年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本内科学会-関東地方会  

    researchmap

  • 日本人全身性強皮症(SSc)におけるBTB and CNS homology 2(Bach2)遺伝子多型(SNPs)の検討

    高木香恵, 川口鎮司, 川本学, 大田ゆう子, 樋口智昭, 深澤千賀子, 栃本明子, 市田久恵, 山中寿

    日本リウマチ学会総会・学術集会プログラム・抄録集   59th   2015年

    　詳細を見る

  • 血清IL‐6,IL‐8,IL‐10は,多発性筋炎・皮膚筋炎関連間質性肺病変における高フェリチン血症の病態に関与する

    川澄日出長, 五野貴久, 川口鎮司, 勝又康弘, 花岡成典, 片岡さゆり, 高木香恵, 市田久恵, 栃本明子, 馬場さゆみ, 岡本祐子, 大田ゆう子, 山中寿

    日本リウマチ学会総会・学術集会プログラム・抄録集   58th   434   2014年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 日本人全身性強皮症(SSc)におけるHypoxia Inducible Factor 1A(HIF1A)遺伝子多型の検討

    高木香恵, 川口鎮司, 川本学, 大田ゆう子, 樋口智昭, 栃本明子, 深澤千賀子, 市田久恵, 勝又康弘, 五野貴久, 山中寿

    日本リウマチ学会総会・学術集会プログラム・抄録集   58th   368   2014年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 強皮症における病因解明と根治的治療法の開発 TGF-β1刺激下におけるシルデナフィルの抗線維化作用に関する検討

    川口鎮司, 樋口智昭, 高木香恵, 栃本明子, 大田ゆう子

    強皮症における病因解明と根治的治療法の開発 平成25年度 総括・分担研究報告書   2014年

    　詳細を見る

  • Analysis Of Relationship Between Clinical Manifestations and Autoantibody Profile In ISN/RPS Class V Lupus Nephritis

    Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hisashi Yamanaka, Yasuhiro Katsumata, Kae Takagi, Hirotaka Kaneko, Hisae Ichida, Yuko Ota, Hidenaga Kawasumi, Sayumi Baba, Yuko Okamoto, Sayuri Kataoka

    ARTHRITIS AND RHEUMATISM   65   S255 - S255   2013年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：WILEY-BLACKWELL  

    Web of Science

    researchmap

  • THE IL12RB2 GENE IS A NOVEL CANDIDATE SUSCEPTIBLE TO SYSTEMIC SCLEROSIS IN THE JAPANESE POPULATION

    Y. Ota, Y. Kawaguchi, T. Nishimoto, M. Kuwana, H. Ichida, T. Gono, H. Yamanaka

    ANNALS OF THE RHEUMATIC DISEASES   72   832 - 832   2013年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：BMJ PUBLISHING GROUP  

    Web of Science

    researchmap

  • リウマチ性疾患にみられる筋病変と合併症 皮膚筋炎と血球貪食症候群/マクロファージ活性化症候群

    勝又康弘, 五野貴久, 大田ゆう子

    月刊リウマチ科   49 ( 4 )   398 - 402   2013年4月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 強皮症の間質性肺病変に関連する因子の検討

    小谷 俊雄, 保田 晋助, 大田 ゆう子, 藤枝 雄一郎, 近 祐次郎, 堀田 哲也, 川口 鎮司, 渥美 達也, 山中 寿, 小池 隆夫

    北海道醫學雜誌 = Acta medica Hokkaidonensia   88 ( 2 )   108 - 108   2013年4月

    　詳細を見る

    記述言語：日本語  

    CiNii Books

    researchmap

  • 全身性強皮症におけるIL‐12RB2遺伝子多型の検討

    大田ゆう子, 川口鎮司, 高木香恵, 市田久恵, 勝又康弘, 五野貴久, 馬場さゆみ, 花岡成典, 岡本祐子, 山中寿

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集   57th-22nd   308   2013年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 強皮症における病因解明と根治的治療法の開発 シルデナフィルの抗線維化作用に関する研究

    川口鎮司, 樋口智昭, 大田ゆう子

    強皮症における病因解明と根治的治療法の開発 平成24年度 総括・分担研究報告書   2013年

    　詳細を見る

  • 肺高血圧症合併強皮症患者の予後についての検討

    高木香恵, 川口鎮司, 大田ゆう子, 樋口智昭, 市田久恵, 勝又康弘, 五野貴久, 山中寿

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集   57th-22nd   2013年

    　詳細を見る

  • シルデナフィルの抗線維化作用に関する検討

    樋口智昭, 川口鎮司, 高木香恵, 大田ゆう子, 山中寿

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集   57th-22nd   2013年

    　詳細を見る

  • 抗CADM‐140抗体価,血清フェリチン,血清IL‐18は,抗CADM‐140抗体陽性皮膚筋炎に併発する間質性肺病変の治療反応性の指標として有用である

    五野貴久, 川口鎮司, 佐藤慎二, 桑名正隆, 勝又康弘, 花岡成典, 片岡さゆり, 高木香恵, 市田久恵, 馬場さゆみ, 岡本祐子, 大田ゆう子, 山中寿

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集   56th-21st   373   2012年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 皮膚筋炎における抗MDA5抗体関連間質性肺炎の臨床像の特徴および予後因子

    五野貴久, 川口鎮司, 佐藤隆司, 桑名正隆, 勝又康弘, 高木香恵, 益田郁子, 市田久恵, 栃本明子, 馬場さゆみ, 花岡成典, 岡本祐子, 大田ゆう子, 片岡さゆり, 山中寿

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集   55th-20th   253   2011年6月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • CD244の遺伝子多型と全身性エリテマトーデスの関連

    大田ゆう子, 川口鎮司, 川本学, 高木香恵, 勝又康弘, 五野貴久, 栃本明子, 山中寿

    日本臨床免疫学会会誌   32 ( 5 )   415   2009年10月

    　詳細を見る

  • CD244の遺伝子多型と全身性エリテマトーデスの関連

    大田 ゆう子, 川口 鎮司, 川本 学, 高木 香恵, 勝又 康弘, 五野 貴久, 栃本 明子, 山中 寿

    日本臨床免疫学会総会抄録集   37 ( 0 )   123 - 123   2009年

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本臨床免疫学会  

    （目的）CD244は、signaling lymphocyte activation molecule (SLAM)のファミリーに属しており、NK細胞やT細胞における免疫反応に重要な働きを担っている。さらに、SLAMファミリーに属しているLy108遺伝子変異がループスマウスで発見されたことより、SLAMファミリー遺伝子と全身性エリテマトーデス(SLE)との関連が推測されていた。今回、我々は、CD244遺伝子多型とSLE発症および、その臨床症状との関連を検討した。<BR>（方法）243例のSLE、756例の健常人のgenomic DNAを抽出した。CD244遺伝子多型は、rs3766379とrs6682654をTaqMan probeを用いて解析した。<BR>（結果）rs3766379のalleleにおいて、SLEとの関連が認められた (P = 0.0023, odds ratio: 1.3, 95% confidence interval: 1.0-1.6)。SLEの臨床症状との検討では、神経精神症状と腎炎において、CD244の２カ所の遺伝子多型と有意な関連が認められた(P < 0.0001)。<BR>（結論）CD244の遺伝子多型は、SLEとの関連が再確認された。また、神経精神症状と腎障害に強い関連が認められてことより、CD244遺伝子多型は、重症SLEの指標となる可能性が示唆された。

    researchmap

  • Association between a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population

    Yuko Ota, Yasushi Kawaguchi, Lkuko Masuda, Manabu Kawamoto, Tomoko Sugiura, Chikako Fukasawa, Kae Takagi, En-Li Nishimagi, Hisae Ichida, Makoto Soejima, Masako Hara, Naoyuki Kamatani

    ARTHRITIS AND RHEUMATISM   58 ( 9 )   S927 - S927   2008年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：WILEY-LISS  

    Web of Science

    researchmap

  • 皮膚筋炎に合併した血球貪食症候群(HPS)に強力な免疫抑制療法が奏功した1例

    大田ゆう子, 川口鎮司, 五野貴久, 益田郁子, 若杉大輔, 山中寿, 原まさ子

    日本臨床リウマチ学会プログラム・抄録集   23rd   108   2008年

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

▼全件表示

講演・口頭発表等

  • 全身性強皮症におけるニンテダニブ投与前後の免疫フェノタイプ解析

    大田ゆう子, 岡崎有佳, 桑名正隆

    第66回日本リウマチ学会総会 

    　詳細を見る

    開催年月日： 2022年4月

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • 悪性腫瘍関連筋炎(CAM)における腫瘍組織内Tertiary lymphoid structures(TLS)の病理組織学的特徴

    門田 寛子, 五野 貴久, 大田 ゆう子, 白井 悠一郎, 桑名 正隆, 岳野 光洋

    日本医科大学医学会雑誌  2021年10月  日本医科大学医学会

    　詳細を見る

    開催年月日： 2021年10月

    記述言語：日本語  

    researchmap

  • The effects of nintedanib on immunophenotype in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).

    Zhixing Jiang, Yuko Ota, Yuichiro Shirai, Yoshioki Yamasaki, Masataka Kuwana

    The 65th Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology, 2021 

    　詳細を見る

    開催年月日： 2021年4月

    記述言語：英語   会議種別：口頭発表（一般）  

    researchmap

  • 多発性筋炎・皮膚筋炎:抗ARS抗体、悪性腫瘍 悪性腫瘍関連筋炎(CAM)における腫瘍組織内Tertiary lymphoid structures(TLS)の病理組織学的特徴

    門田 寛子, 五野 貴久, 岡崎 有佳, 大田 ゆう子, 白井 悠一郎, 岳野 光洋, 桑名 正隆

    第65回日本リウマチ学会総会・学術総会  (一社)日本リウマチ学会

    　詳細を見る

    開催年月日： 2021年4月

    記述言語：日本語  

    researchmap

  • 皮膚硬化のピーク時期による早期びまん皮膚硬化型 強皮症の病型分類の試み

    大田ゆう子, 白井悠一郎, 五野貴久, 岳野光洋, 桑名正隆

    第64回日本リウマチ学会総会・学術集会  2020年8月 

    　詳細を見る

    開催年月日： 2020年8月 - 2020年9月

    記述言語：日本語   会議種別：ポスター発表  

    researchmap

  • 強皮症・MCTD・重複症候群 全身性強皮症におけるCTによる食道拡張の臨床的意義

    鈴木 幹人, 白井 悠一郎, 名和田 隆司, 大田 ゆう子, 五野 貴久, 岳野 光洋, 桑名 正隆

    日本リウマチ学会総会・学術集会プログラム・抄録集  2020年8月  (一社)日本リウマチ学会

    　詳細を見る

    開催年月日： 2020年8月

    記述言語：日本語  

    researchmap

  • 強皮症・MCTD・重複症候群 強皮症関連間質性肺疾患患者の経時的胸部骨格筋量減少に寄与する因子の同定

    名和田 隆司, 白井 悠一郎, 大田 ゆう子, 鈴木 幹人, 五野 貴久, 岳野 光洋, 桑名 正隆

    日本リウマチ学会総会・学術集会プログラム・抄録集  2020年8月  (一社)日本リウマチ学会

    　詳細を見る

    開催年月日： 2020年8月

    記述言語：日本語  

    researchmap

  • Increased collagen production by Fli1 KO NIH3T3 fibroblasts is not suppressed by TGF-1 or IL-6 antibodies.

    Ota Y, Kitani A, Strober W

    Keystone Symposia;Injury, Inflammation;Fibrosis  2017年3月 

    　詳細を見る

    開催年月日： 2017年3月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Homozygous Fli-1 knockout fibroblast cell line targeted by Crispr-Cas9 shows pro-fibrotic characteristics.

    Ota Y, Mao L, Choi U, Strober W, Kitani A

    Keystone Symposia, Fibrosis: From Basic Mechanisms to Targeted Therapies, 2016  2016年2月 

    　詳細を見る

    開催年月日： 2016年2月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts.

    Tomoaki Higuchi, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuko Ota, Yasuhiro Katsumata, Takahisa Gono, Masanori Hanaoka, Yuko Okamoto, Hidenaga Kawasumi, Hisashi Yamanaka

    The 78th Annual Scientific Meeting of American College of Rheumatology  2014年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2014年10月

    記述言語：英語  

    researchmap

  • Endothelin-1 Is a Downstream Mediator of Profibrotic Effects by Transforming Growth Factor-beta 1 in Systemic Sclerosis Skin Fibroblasts.

    Tomoaki Higuchi, Yasushi Kawaguchi, Akiko Tochimoto, Yuko Ota, Yasuhiro Katsumata, Takahisa Gono, Masanori Hanaoka, Yuko Okamoto, Hidenaga Kawasumi, Hisashi Yamanaka

    The 78th Annual Scientific Meeting of American College of Rheumatology  2014年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2014年10月

    記述言語：英語  

    researchmap

  • IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis

    Ota Y, Kawaguchi Y, Kitani A, Strober W

    Keystone Symposia, Fibrosis: From Bench to Bedside, 2014  2014年3月 

    　詳細を見る

    開催年月日： 2014年3月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Identification Of Autoantibodies To Tyrosyl-Transfer RNA Synthetase Associated With Anti-Synthetase Syndrome

    Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Koji Tahara, Kaori Ito, Hiroaki Hattori, Takahisa Gono, Kae Takagi, Masanori Hanaoka, Yuko Ota, Hidenaga Kawasumi, Hisashi Yamanaka

    The 77th Annual Scientific Meeting of American College of Rheumatology  2013年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2013年10月

    記述言語：英語  

    researchmap

  • Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation- Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl tRNA Synthetase Antibody-Associated Interstitial Lung Disease

    Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Hidenaga Kawasumi, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota, Hisashi Yamanaka

    The 77th Annual Scientific Meeting of American College of Rheumatology  2013年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2013年10月

    記述言語：英語  

    researchmap

  • Analysis Of The Associations Between Serum Ferritin and Cytokines In Pulmonary Disease Activity With Polymyositis/Dermatomyositis

    Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota, Hisashi Yamanaka

    The 77th Annual Scientific Meeting of American College of Rheumatology  2013年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2013年10月

    記述言語：英語  

    researchmap

  • Pirfenidone and BIBF1120 Suppress Collagen Synthesis In Skin Fibroblast From Patients With Systemic Sclerosis

    Yuko Ota, Yasushi Kawaguchi, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Takahisa Gono, Yuko Okamoto, Tomoaki Higuchi, Hidenaga Kawasumi, Hisashi Yamanaka

    The 77th Annual Scientific Meeting of American College of Rheumatology  2013年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2013年10月

    記述言語：英語  

    researchmap

  • 全身性強皮症皮膚線維芽細胞におけるIL-13作用の検討

    大田 ゆう子, 川口鎮司, 木谷敦, 高木香恵, 市田久恵, 勝又康弘, 五野貴久, 花岡成典, 山中寿

    第57回 日本リウマチ学会 総会・学術集会  2013年4月 

    　詳細を見る

    開催年月日： 2013年4月

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • 全身性強皮症におけるIL-12RB2遺伝子多型の検討

    大田ゆう子, 川口鎮司, 高木香恵, 市田久恵, 勝又康弘, 五野貴久, 馬場さゆみ, 花岡成典、岡本祐子、山中寿

    第57回 日本リウマチ学会 総会・学術集会  2013年4月 

    　詳細を見る

    開催年月日： 2013年4月

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • Validity and Reliability of the Lupus Damage Index Questionnaire (LDIQ): A Prospective Study

    Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota, Hisashi Yamanaka

    The 76th Annual Scientific Meeting of American College of Rheumatology  2012年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語  

    researchmap

  • Clinical Manifestations and Predictive Factors for Response to Induction Therapy and Maintenance of Remission in ISN/RPS Class V Lupus Nephritis.

    Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Yuko Okamoto, Yuko Ota, Sayuri Kataoka, Hisashi Yamanaka

    The 76th Annual Scientific Meeting of American College of Rheumatology  2012年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語  

    researchmap

  • Validity and Reliability of the Systemic Lupus Activity Questionnaire (SLAQ): A Prospective Study.

    Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota, Hisashi Yamanaka

    The 76th Annual Scientific Meeting of American College of Rheumatology  2012年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語  

    researchmap

  • IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis

    Yuko Ota, Yasushi Kawaguchi, Atsushi Kitani, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Takahisa Gono, Masanori Hanaoka, Yuko Okamoto, Hisashi Yamanaka

    The 76th Annual Scientific Meeting of American College of Rheumatology  2012年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語  

    researchmap

  • IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis.

    Ota Y, Kawaguchi Y, Kitani A, Takagi K, Ichida H, Katsumata Y, Gono T, Hanaoka M, Okamoto Y, Yamanaka H

    The 76th annual meeting of American College of Rheumatology, Washington D.C., USA, 2012  2012年10月 

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Line Blot Assay, a Screening Test for Autoantibodies in Systemic Sclerosis (SSc).

    Kae Takagi, Yasushi Kawaguchi, Sayuri Kataoka, Yuko Ota, Yuko Okamoto, Masanori Hanaoka, Hisae Ichida, Takahisa Gono, Yasuhiro Katsumata, Hisashi Yamanaka

    The 76th Annual Scientific Meeting of American College of Rheumatology  2012年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語  

    researchmap

  • HLA-DRB1*0101/*0405 Is Associated with Susceptibility to Anti-MDA5 Antibody-Positive Dermatomyositis in the Japanese Population.

    Takahisa Gono, Yasushi Kawaguchi, Masataka Kuwana, Tomoko Sugiura, Takefumi Furuya, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Masanori Hanaoka, Yuko Okamoto, Yuko Ota, Sayuri Kataoka, Hisashi Yamanaka

    The 76th Annual Scientific Meeting of American College of Rheumatology  2012年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2012年10月

    記述言語：英語  

    researchmap

  • Decreased plasma ghrelin levels in patents with systemic sclerosis

    Ota Y, Kawaguchi Y, Takagi K, Ichida H, Gono T, Hanaoka M, Yamanaka H

    The 75th annual meeting of American College of Rheumatology, Chicago, USA, 2011  2011年10月 

    　詳細を見る

    開催年月日： 2011年10月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Atorvastatin attenuates skin fibrosis through the PI3K pathway.

    Ota Y, Kawaguchi Y, Takagi K, Ichida H, Gono T, Hanaoka M, Yamanaka H

    The 75th annual meeting of American College of Rheumatology, Chicago, USA, 2011  2011年10月 

    　詳細を見る

    開催年月日： 2011年10月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Notch Pathway Is Activated in Systemic Sclerosis (SSc)

    Kae Takagi, Yasushi Kawaguchi, Yuko Ota, Akiko Tochimoto, Chikako Fukasawa, Masanori Hanaoka, Hisae Ichida, Takahisa Gono, Hisashi Yamanaka

    The 75th Annual Scientific Meeting of American College of Rheumatology  2011年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2011年10月

    記述言語：英語  

    researchmap

  • Classification of Two Subtypes in Adult-Onset Still's Disease.

    Hisae Ichida, Yasushi Kawaguchi, Tomoko Sugiura, Takahisa Gono, Kae Takagi, Yuko Ota, Ikuko Masuda, Hisashi Yamanaka

    The 75th Annual Scientific Meeting of American College of Rheumatology  2011年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2011年10月

    記述言語：英語  

    researchmap

  • Urinary lambda Free Light Chain Concentration Is Associated with Disease Activity and Response to Treatment in Proliferative Lupus Nephritis

    Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yumi Koseki, Yasuhiro Katsumata, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota, Sayuri Kataoka, Hisashi Yamanaka

    The 75th Annual Scientific Meeting of American College of Rheumatology  2011年10月  WILEY-BLACKWELL

    　詳細を見る

    開催年月日： 2011年10月

    記述言語：英語  

    researchmap

  • Association between a polymorphism of the IRAK-1 gene and susceptibility to systemic lupus erythematosus in the Japanese population.

    Ota Y, Kawaguchi Y, Kawamoto M, Takagi K, Tochimoto A, Yamanaka H

    The 14th Asia Pacific League of Associations for Rheumatology Congress, Hong Kong, China, 2010  2010年7月 

    　詳細を見る

    開催年月日： 2010年7月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • 全身性強皮症患者における血漿中グレリン濃度の検討

    大田ゆう子, 川口鎮司, 益田郁子, 高木香恵, 勝又康弘, 五野貴久, 栃本明子, 原まさ子, 山中寿

    第54回日本リウマチ学会総会  2010年4月 

    　詳細を見る

    開催年月日： 2010年4月

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • Association Study of the IRAK1 Gene with Susceptibility to Systemic Lupus Erythematosus and Systemic Sclerosis.

    Ota Y, Kawaguchi Y, Kawamoto M, Takagi K, Tochimoto A, Katsumata Y, Gono T, Baba S, Okamoto Y, Yamanaka H

    The 74th annual meeting of American College of Rheumatology, Atlanta, USA, 2010  2010年 

    　詳細を見る

    開催年月日： 2010年

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Association Study of a Polymorphism of the CD244 Gene with Susceptibility to Systemic Lupus Erythematosus and with Clinical features.

    Ota Y, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Hara M, Yamanaka H

    The 73rd annual meeting of American College of Rheumatology, Philadelphia, USA, 2009  2009年10月 

    　詳細を見る

    開催年月日： 2009年10月

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • PI3K-Akt pathway plays a crucial role in production of collagen in Fli1 deficient condition and its inhibitor has the therapeutic potential in treating fibrosis.

    Yuko Ota, Warren Strober, Atsushi Kitani

    第63回日本リウマチ学会総会・学術集会  2019年4月 

    　詳細を見る

    記述言語：英語   会議種別：口頭発表（一般）  

    researchmap

  • 全身性強皮症発症とCTGF遺伝子多型の関連

    大田ゆう子, 川口鎮司, 伊東郁恵, 土屋尚之, 桑名正隆, 佐藤伸一, 竹原和彦, 山中寿, 原まさ子

    第106回日本内科学会総会  2009年4月 

    　詳細を見る

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. 国際会議

    Ota Y, Kawaguchi Y, Masuda I, Kawamoto M, Sugiura T, Fukasawa C, Takagi K, Nishimagi E, Ichida H, Soejima M, Masako H, Kamatani N

    The 72nd annual meeting of the American College of Rheumatology, San Francisco, USA  2008年11月 

    　詳細を見る

    記述言語：英語   会議種別：口頭発表（一般）  

    researchmap

  • 強皮症患者のレイノー現象に対するプラバスタチンの治療成

    大田ゆう子 , 川口鎮司 , 高木香恵 , 市田久恵 , 勝又康弘 , 栃本明子 , 山中寿 , 原まさ子

    第53回日本リウマチ学会総会  2009年4月 

    　詳細を見る

    記述言語：日本語   会議種別：ポスター発表  

    researchmap

▼全件表示

受賞

  • JSPS Research Fellowship at NIH (Kaitoku-NIH)

    2017年   日本学術振興会  

    大田ゆう子

    　詳細を見る

  • APLAR 2010 travel grant on the Jaoan College of Rheumatology

    2010年   日本リウマチ学会  

    大田ゆう子

    　詳細を見る

共同研究・競争的資金等の研究課題

  • 網羅的遺伝子解析を用いた強皮症特異的単球master regulatorの同定

    研究課題/領域番号：21K16310  2021年4月 - 2023年3月

    日本学術振興会  科学研究費助成事業 若手研究  若手研究

    井関 ゆう子

    　 詳細を見る

    配分額：4550000円 （ 直接経費：3500000円 、 間接経費：1050000円 ）

    全身性強皮症（SSc）は血管内皮障害および線維化を特徴とする疾患である。単球・マクロファージがその病態に重要な役割を果たしていることは知られているが、SSc特異的単球・マクロファージの同定には至っていない。本研究は、in vitroで分化誘導したマクロファージの網羅的遺伝子解析から、異なる誘導因子によるマクロファージ分化誘導のmaster regulatorを同定し、それらを元にmaster regulator抽出アルゴリズムを構築する。構築したアルゴリズムを用いてSSc単球RNA-seq及び末梢血単核球single cell RNA-seqデータを解析し、SSc特異的単球・マクロファージにおけるmaster regulatorを同定することを目的としている。
    本年度は、まず各誘導マクロファージの遺伝子発現の網羅的解析を行う際のコンディション調整を行った。末梢血単核球を密度勾配法にて抽出し、magnetic beadsでCD14+単球を単離し、CSF-1を初めとする各種成長因子、サイトカイン、ケモカイン添加のもと培養し、total RNAを抽出する。この過程において、誘導因子の濃度変化や培養時間の調整により、cell viability等を検討し、最適な誘導条件を設定した。さらに、既報を参考に、発現変動遺伝子の抽出、pathway解析、データの統合といったRNA-seqおよびcsRNA-seqデータの解析手法を習得した。
    今後は、早急に異なる因子により誘導したマクロファージの網羅的遺伝子解析を行い、master regulatorの同定を行いたいと考えている。

    researchmap

  • 全身性強皮症におけるM4マクロファージの役割

    2019年8月 - 2021年3月

    日本学術振興会  科学研究費助成事業 

    大田ゆう子

    　 詳細を見る

    担当区分：研究代表者  資金種別：競争的資金

    researchmap